CNP inhibits T3 - induced hypertrophic growth in H9c2 cells: Impact of HDAC inhibitor
Archives of Biochemistry and Biophysics · 2026-01 · 775 · 110648
DOI: 10.1016/j.abb.2025.110648 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Biochemistry and Biophysics, 2026-01. Verfasst von Gopinath Nagaraj und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry (Peptide Research and Molecular Cardiology Unit), University of Madras, Guindy Campus, Chennai, 600 025, Tamil Nadu, India…. Hauptthemen laut MEDLINE: Natriuretic Peptide, C-Type, Histone Deacetylase Inhibitors, Myocytes, Cardiac, Cardiomegaly. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: University of Madras, Rashtriya Uchchatar Shiksha Abhiyan.
Abstract (Originalsprache)
C-type natriuretic peptide (CNP) is a multifaceted paracrine factor that regulates vital physiological functions of the cardiovascular system. The present study was designed to investigate the anti-hypertrophic activity of CNP in the presence and absence of HDAC inhibitor Suberoylanilide hydroxamic acid (SAHA) in T3-induced H9c2 cells. The H9c2 cells were treated with T3 (10 nM) for 48 hours to induce hypertrophic growth. T3 alone-treated cells exhibited an increase in cell size (p < 0.001) as compared with control H9c2 cells. CNP treatment effectively reverted the increased cell size by 61 %, and also altered the expression of hypertrophic marker genes. Interestingly, a significantly enhanced anti-hypertrophic activity was noticed in CNP co-treatment with SAHA, and also a more significant decrease in the expression of hypertrophic marker genes (α-sk, and α-MHC) was also observed. Moreover, CNP treatment with SAHA effectively reversed the T3-induced changes in the expression of Npr1 and Npr2 genes in H9c2 cells. In addition, CNP co-treated with SAHA reversed the T3-induced abnormal calcium influx by normalizing of CaMKII and SERCA2a. The findings of the present study clearly show that CNP co-treatment with SAHA significantly enhances the CNP-mediated anti-hypertrophic activity, probably by restoring Npr1 and Npr2 gene expression and calcium influx. Taken together, we conclude that CNP in combination with SAHA represents a novel therapeutic approach for the treatment and management of cardiac hypertrophy and heart failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry (Peptide Research and Molecular Cardiology Unit), University of Madras, Guindy Campus, Chennai, 600 025, Tamil Nadu, India. Electronic address: gopinath11913@gmail.com.
- Department of Biochemistry (Peptide Research and Molecular Cardiology Unit), University of Madras, Guindy Campus, Chennai, 600 025, Tamil Nadu, India. Electronic address: vellaie@gmail.com.
Förderung
- University of Madras
- Rashtriya Uchchatar Shiksha Abhiyan
Zitieren
APA
Nagaraj, G., & Vellaichamy, E. (2026). CNP inhibits T3 - induced hypertrophic growth in H9c2 cells: Impact of HDAC inhibitor. Archives of Biochemistry and Biophysics, 775, 110648. https://doi.org/10.1016/j.abb.2025.110648
Vancouver
Nagaraj G, Vellaichamy E. CNP inhibits T3 - induced hypertrophic growth in H9c2 cells: Impact of HDAC inhibitor. Archives of Biochemistry and Biophysics. 2026;775:110648. doi:10.1016/j.abb.2025.110648
BibTeX
@article{Nagaraj2026,
author = {Nagaraj, Gopinath and Vellaichamy, Elangovan},
title = {CNP inhibits T3 - induced hypertrophic growth in H9c2 cells: Impact of HDAC inhibitor},
journal = {Archives of Biochemistry and Biophysics},
year = {2026},
volume = {775},
pages = {110648},
doi = {10.1016/j.abb.2025.110648}
}
EUVIMED